Shanghai Junshi Bioscience Co., Ltd.
junshipharma.comTotal trials
97
Active
29
Phase 3
25
Total enrollment
21,016
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Toripalimab | — | — | 19 | ||||
| Paclitaxel | — | — | — | — | 4 | ||
| Irinotecan | — | — | — | — | 2 | ||
| JS002 | — | — | — | 6 | |||
| Cisplatin | — | — | — | — | 2 | ||
| Docetaxel | — | — | — | — | 2 | ||
| JS004 in combination with Toripalimab | — | — | — | — | 2 | ||
| Lenvatinib mesylate | — | — | — | — | — | 1 | |
| Oral placebo | — | — | — | — | — | 1 | |
| Oxaliplatin for | — | — | — | — | — | 1 | |
| Gemcitabine hydrochloride | — | — | — | — | — | 1 | |
| Toripalimab combined with cisplatin and paclitaxel | — | — | — | — | — | 1 | |
| JS001/Placebo | — | — | — | — | — | 1 | |
| JS001/placebo combine with Postoperative Adjuvant Chemotherapy | — | — | — | — | — | 1 | |
| 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab | — | — | — | — | — | 1 | |
| 4cycles | — | — | — | — | — | 1 | |
| Tifcemalimab | — | — | — | — | — | 1 | |
| JS107 for | — | — | — | — | — | 1 | |
| Bendamustine or gemcitabine | — | — | — | — | — | 1 | |
| Toripalimab combined with Lenvatinib | — | — | — | — | — | 1 | |
| JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy | — | — | — | — | — | 1 | |
| JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy | — | — | — | — | — | 1 | |
| JS207 | — | — | — | — | 9 | ||
| Capecitabine | — | — | — | — | 4 | ||
| Oxaliplatin | — | — | — | — | 4 | ||
| Pemetrexed | — | — | — | — | 4 | ||
| JS212 for | — | — | — | — | — | 3 | |
| JS212 | — | — | — | — | — | 3 | |
| Bevacizumab | — | — | — | — | 3 | ||
| JS015 | — | — | — | — | 3 | ||
| JS207 for | — | — | — | — | — | 2 | |
| JS213 for | — | — | — | — | — | 2 | |
| JS001 | — | — | — | 3 | |||
| JS007 | — | — | — | — | 2 | ||
| JS212 for Injection＋JS111 | — | — | — | — | — | 1 | |
| JS207 in combination with 9MW2821 | — | — | — | — | — | 1 | |
| JS207 in combination with Albumin paclitaxel | — | — | — | — | — | 1 | |
| Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma | — | — | — | — | — | 1 | |
| Platinum | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 |
18 more active programs hidden
Next readouts
- 2024-09-23
- 2025-05-31
- 2025-06-30
- 2025-11-01
- 2025-11-30
- 2025-12-31
- 2025-12-31
- 2026-05-15
- 2026-06-26
- 2026-06-30
Top conditions
- Hyperlipemia4
- Hepatocellular Carcinoma3
- Melanoma3
- Advanced Hepatocellular Carcinoma (HCC)3
- Advanced Lung Cancer3
- NSCLC3
- Advanced Cancer2
- Advanced Melanoma2
Frequently asked questions about Shanghai Junshi Bioscience Co., Ltd.
- How many clinical trials does Shanghai Junshi Bioscience Co., Ltd. have on ClinicalTrials.gov?
- Shanghai Junshi Bioscience Co., Ltd. is listed as the lead sponsor on 97 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shanghai Junshi Bioscience Co., Ltd.'s trials are in Phase 3?
- 25 of Shanghai Junshi Bioscience Co., Ltd.'s trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does Shanghai Junshi Bioscience Co., Ltd. focus on?
- Shanghai Junshi Bioscience Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Hyperlipemia, Hepatocellular Carcinoma, Melanoma, Advanced Hepatocellular Carcinoma (HCC), Advanced Lung Cancer.
- When are Shanghai Junshi Bioscience Co., Ltd.'s next clinical trial readouts?
- Shanghai Junshi Bioscience Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia”, expected around 2024-09-23.